CSIMarket Company Name, Ticker, Suppliers, else..
 
Contineum Therapeutics Inc   (NASDAQ: CTNM)
Other Ticker:  
 
 
Price: $4.7600 $1.11 30.411%
Day's High: $4.87 Week Perf: 2.81 %
Day's Low: $ 3.71 30 Day Perf: 35.61 %
Volume (M): 298 52 Wk High: $ 22.00
Volume (M$): $ 1,417 52 Wk Avg: $12.69
Open: $3.71 52 Wk Low: $3.35



 Market Capitalization (Millions $) 123
 Shares Outstanding (Millions) 26
 Employees 10
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -50
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 0

Contineum Therapeutics Inc


   Company Address: 3565 General Atomics Court, Suite 200 San Diego 92121 CA
   Company Phone Number: 333-5280   Stock Exchange / Ticker: NASDAQ CTNM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -3.02%    
ABT   -1.94%    
BMY   -5.81%    
JNJ   -4.65%    
MRK   -3.24%    
PFE   -2.32%    
• View Complete Report
   



Business Update

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Dru...

Published Mon, Nov 18 2024 1:47 PM UTC

Expanding Horizons: Contineum Therapeutics Advances Chronic Pain Treatment with New IND AuthorizationContineum Therapeutics, Inc. a clinical-stage biopharmaceutical company, is making significant strides in the realm of pain management with the recent authorization of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for its thera...
Business Update

Breakthrough in Biopharmaceutical Science Promising Data on PIPE-307, an M1 Receptor Antagonist for Relapse-Remitting...

Published Thu, Aug 1 2024 6:28 AM UTC

The development of novel therapeutic agents has become an imperative focus in the biomedical field, particularly for conditions lacking fully effective treatment options. Recent preclinical data published in the Proceedings of the National Academy of Sciences (PNAS) revealed encouraging findings for PIPE-307, an M1 receptor antagonist currently in development by Contineum T...
Business Update

Sarah Boyce Joins Contineum Therapeutics Board A Step Towards Augmenting Biopharmaceutical Therapies

Published Tue, Jun 25 2024 12:47 AM UTC

Sarah Boyce Appointed to Contineum Therapeutics Board of Directors: Strengthening the Clinical Stage Biopharmaceutical Company s Drug Development StrategiesIn recent news, Contineum Therapeutics, a clinical stage biopharmaceutical company focused on the discovery and development of novel, oral small molecule therapies targeting biological pathways associated with specific c...
Business Update

Contineum Therapeutics Strengthens Leadership Team with the Strategic Appointment of Sarah Boyce to its Board of Dire...

Published Mon, Jun 24 2024 10:47 PM UTC

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors SAN DIEGO Contineum Therapeutics, Inc. (Nasdaq: CTNM), a forward-thinking clinical stage biopharmaceutical company, has further solidified its executive leadership through the strategic addition of Sarah Boyce to its Board of Directors. Underlying this significant appointment is Contineum The...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com